Log in

Relevant bibliographies by topics / Trials / Journal articles

To see the other types of publications on this topic, follow the link: Trials.

Journal articles on the topic 'Trials'

Author: Grafiati

Published: 4 June 2021

Last updated: 25 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Trials.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Rujuta, Saksena, and M. Mehnert Janice. "Ignorance is not bliss: The importance of publishing negative trials." Biohelikon 2, no. 1 (2014): 1–3. https://doi.org/10.5281/zenodo.814311.

Full text

Abstract:

It is not surprising that, in medicine, positive trials tend to generate more excitement compared with negative trials. Positive studies may be perceived as more likely to change the scope of one’s clinical practice. In general, negative studies attract less attention from different parties, including authors, editors, peer-reviewers, physicians, and readers of medical literature. Indeed, industry sponsors and principal investigators may hesitate to publish negative studies if critical acclaim of the work is not anticipated.

APA, Harvard, Vancouver, ISO, and other styles

2

Van Der Weyden, Martin B. "Trials on trial." Medical Journal of Australia 175, no. 5 (2001): 241. http://dx.doi.org/10.5694/j.1326-5377.2001.tb143553.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Nelson, Mark. "Trials on trial." New Scientist 209, no. 2800 (2011): 30. http://dx.doi.org/10.1016/s0262-4079(11)60384-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Vulto, Arnold G. "Clinical trials on trial." European Journal of Hospital Pharmacy 19, no. 4 (2012): 347. http://dx.doi.org/10.1136/ejhpharm-2012-000180.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Karki, Naresh. "â€œSolidarity Trialâ€: A Feeling of Trust Towards COVID-19 Treatments." Journal of Lumbini Medical College 8, no. 1 (2020): 164–65. http://dx.doi.org/10.22502/jlmc.v8i1.335.

Full text

Abstract:

Corona Virus Disease (COVID-19) drugs are not being developed at the pace in which the disease is spreading throughout the world. WHO and its partners have announced the worldwide clinical trial on 18th March 2020, known as â€œSolidarity Trialâ€ for greater co-ordination of developments of drugs. â€œSolidarity Trialis an international clinical trial to help find an effective treatment for COVID-19â€. The trial is randomized, open-label and adaptive. This trial will analyze four treatment options against standard of care, after recruiting patients from various countries, and then will approac

APA, Harvard, Vancouver, ISO, and other styles

6

Foster, Henry H. "TRIAL MARRIAGES AND DIVORCE TRIALS." Family Court Review 11, no. 1 (2005): 1–7. http://dx.doi.org/10.1111/j.174-1617.1973.tb01183.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Harman, Chloë. "Putting clinical trials on trial." Nature Reviews Nephrology 5, no. 6 (2009): 301. http://dx.doi.org/10.1038/nrneph.2009.89.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

MIZUSHIMA, YUTAKA. "New trials of trial cases." Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 29, no. 1/2 (1998): 1–6. http://dx.doi.org/10.3999/jscpt.29.1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Palca, J. "Government ddI trials on trial." Science 246, no. 4935 (1989): 1244. http://dx.doi.org/10.1126/science.2511632.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Moyé, Lemuel A., and Anita Deswal. "Trials within Trials." Controlled Clinical Trials 22, no. 6 (2001): 605–19. http://dx.doi.org/10.1016/s0197-2456(01)00180-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Weinberg, Jeffrey. "Clinical Trials in Progress: ROADS Trial." ONCOLOGY, no. 3508 (August 2021): 495. http://dx.doi.org/10.46883/onc.2021.3508.0495.

Full text

Abstract:

Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) versus Surgically Targeted Radiation Therapy (STaRT) with GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors (ROADS; NCT04365374).

APA, Harvard, Vancouver, ISO, and other styles

12

Dean, Rachel S. "Veterinary clinical trials are on trial." Veterinary Record 181, no. 8 (2017): 193–94. http://dx.doi.org/10.1136/vr.j3867.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Ranganathan, Priya, Vishal Deo, C. S. Pramesh, and Mahesh P. Parmar. "Novel trial designs: Master protocol trials." Perspectives in Clinical Research 16, no. 1 (2024): 50–53. https://doi.org/10.4103/picr.picr_214_24.

Full text

Abstract:

Abstract Conventional trial designs are resource and time-intensive. To accelerate the process of testing new interventions, we now have several novel research trial designs. This article focuses on master protocol trials, which allow several therapies to be tested within a single larger trial.

APA, Harvard, Vancouver, ISO, and other styles

14

Rokhsefat, Sana, Deanna E. Morra, Martin Offringa, Lisa M. Askie, and Lauren E. Kelly. "Trial registration in pediatric surgery trials." Journal of Pediatric Surgery 53, no. 7 (2018): 1273–79. http://dx.doi.org/10.1016/j.jpedsurg.2017.10.049.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Curtis, John J., and Bruce Kaplan. "Transplant Immunosuppressive Drug Trials on Trial." American Journal of Transplantation 4, no. 5 (2004): 671–72. http://dx.doi.org/10.1111/j.1600-6143.2004.00474.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Graham, H. Kerr. "The trials of trials." Developmental Medicine & Child Neurology 49, no. 3 (2007): 163. http://dx.doi.org/10.1111/j.1469-8749.2007.00163.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Prashant, Singar* Apurva Torane Mayur Paithankar Anuja Jadhav Sakshi Shahane. "The Importance of Clinical Trials in New Drug Design." International Journal of Pharmaceutical Sciences 2, no. 11 (2024): 530–41. https://doi.org/10.5281/zenodo.14062794.

Full text

Abstract:

Clinical exploration is an elective wording used to portray clinical examination. Clinical exploration includes individuals, and it is for the most part completed to assess the viability of a helpful medication, a clinical/careful strategy, or a gadget as a piece of treatment and patient administration. In addition, any exploration that assesses the parts of an infection like the side effects, risk factors, and pathophysiology, among others may be named clinical examination. Notwithstanding, clinical preliminaries are those reviews that evaluate the capability of a restorative medication/gadge

APA, Harvard, Vancouver, ISO, and other styles

18

Patel, Khushru. "Envisioning Data in Clinical Trials." International Journal of Science and Research (IJSR) 11, no. 9 (2022): 1068. http://dx.doi.org/10.21275/sr22926130141.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Santhosh R Divya, Samuel. "In Silico Clinical Trials - Review." International Journal of Science and Research (IJSR) 12, no. 6 (2023): 262–66. http://dx.doi.org/10.21275/sr23512133636.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

de Vries, Ymkje Anna, Annelieke M. Roest, Erick H. Turner, and Peter de Jonge. "Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials." Psychological Medicine 49, no. 12 (2018): 2020–26. http://dx.doi.org/10.1017/s0033291718002805.

Full text

Abstract:

AbstractBackgroundPrevious studies on reporting bias generally examined whether trials were published in stand-alone publications. In this study, we investigated whether pooled-trials publications constitute a specific form of reporting bias. We assessed whether negative trials were more likely to be exclusively published in pooled-trials publications than positive trials and examined the research questions, individual trial results, and conclusions presented in these articles.MethodsData from a cohort of 105 randomized controlled trials of 16 antidepressants were extracted from earlier public

APA, Harvard, Vancouver, ISO, and other styles

21

Seow, Hsien-Yeang, Patrick Whelan, Mark N. Levine, et al. "Funding Oncology Clinical Trials: Are Cooperative Group Trials Sustainable?" Journal of Clinical Oncology 30, no. 13 (2012): 1456–61. http://dx.doi.org/10.1200/jco.2011.37.2698.

Full text

Abstract:

Purpose Many oncology clinical trials departments (CTDs) are in serious fiscal deficit and their sustainability is in jeopardy. This study investigates whether the payment models used to fund industry versus cooperative group trials contribute to the fiscal deficit of a CTD. Methods We examined the lifetime costs of all cooperative group and industry trials activated in the CTD of a cancer center between 2007 and 2011. A trial's lifetime is defined as being from the date the first patient was accrued until the last patient's actual or projected final follow-up visit. For each trial, we calcula

APA, Harvard, Vancouver, ISO, and other styles

22

Hughes, Emily, Tamara Van Bakel, Ashley Raudanskis, et al. "Comparing the Clinical Trial Characteristics of Industry-Funded Trials and Non Industry-Funded Trials." Journal of Law, Medicine & Ethics 52, no. 3 (2024): 693–700. https://doi.org/10.1017/jme.2024.135.

Full text

Abstract:

AbstractWe compared study characteristics of randomized controlled trials funded by industry (N=697) to those not funded by industry (N=835). RCTs published in high-impact journals are more likely to be blinded, more likely to include a placebo, and more likely to post trial results on ClinicalTrials.gov. Our findings emphasize the importance of evaluating the quality of an RCT based on its methodological rigor, not its funder type.

APA, Harvard, Vancouver, ISO, and other styles

23

Zarin, Deborah A., and Robert M. Califf. "Trial Reporting and the Clinical Trials Enterprise." JAMA Internal Medicine 181, no. 8 (2021): 1131. http://dx.doi.org/10.1001/jamainternmed.2021.2041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Abd alamir, Moshrik, Susan S. Ellenberg, Ronald S. Swerdloff, et al. "The Cardiovascular Trial of the Testosterone Trials." Coronary Artery Disease 27, no. 2 (2016): 95–103. http://dx.doi.org/10.1097/mca.0000000000000321.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Pardini, Matteo, Gary Cutter, and Maria Pia Sormani. "Clinical trial design for progressive MS trials." Multiple Sclerosis Journal 23, no. 12 (2017): 1642–48. http://dx.doi.org/10.1177/1352458517729461.

Full text

Abstract:

The design of clinical trials is a key aspect to maximizing the possibility to detect a treatment effect. This fact is particularly challenging in progressive multiple sclerosis (PMS) studies due to the uncertainty about the right target and/or outcome in phase-2 studies. The aim of this review is to evaluate the current challenges facing the design of clinical trials for PMS. The selection of patients, the instrumental and clinical outcomes that can be used in PMS trials, and issues in their design will be covered in this report.

APA, Harvard, Vancouver, ISO, and other styles

26

Van Roessel, I. M. A. A., N. I. Mazur, S. K. Shah, L. Bont, and R. Van Der Graaf. "Post-trial Access in Maternal Vaccine Trials." American Journal of Perinatology 36, S 02 (2019): S41—S47. http://dx.doi.org/10.1055/s-0039-1691799.

Full text

Abstract:

AbstractProvisions for post-trial access (PTA) of the experimental intervention are required before the start of a clinical trial. Although there has been ample attention for PTA in the context of preventive vaccine research, discussions on PTA barely include maternal vaccine trials in which mother–infant pairs are exposed to the intervention. In maternal vaccination trials, specific PTA arrangements are required because pregnancy is transient and PTA may apply to the next pregnancy or the child. In this article, we examine the application and adherence to PTA in the context of maternal vaccin

APA, Harvard, Vancouver, ISO, and other styles

27

Ying, Xiangji, and Stephan Ehrhardt. "Pilot Trial Characteristics, Postpilot Design Modifications, and Feasibility of Full-Scale Trials." JAMA Network Open 6, no. 9 (2023): e2333642. http://dx.doi.org/10.1001/jamanetworkopen.2023.33642.

Full text

Abstract:

ImportancePilot trials often lead to study design changes in subsequent full-scale trials. Yet, it remains unclear whether these modifications improve the feasibility of the larger trial.ObjectiveTo compare feasibility estimates between pilot and full-scale trials and identify pilot trial characteristics and modifications associated with equivalent or improved feasibility in the full-scale trial.Design, Setting, and ParticipantsThis cohort study used pilot trials published between January 2005 and December 2018 and their corresponding full-scale trials. PubMed was searched for trials on Februa

APA, Harvard, Vancouver, ISO, and other styles

28

Smigel, K. "The Trials of Prevention Trials." JNCI Journal of the National Cancer Institute 81, no. 15 (1989): 1123–26. http://dx.doi.org/10.1093/jnci/81.15.1123.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

The Lancet. "The trials of tenofovir trials." Lancet 365, no. 9465 (2005): 1111. http://dx.doi.org/10.1016/s0140-6736(05)71850-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Sedgwick, P. "Explanatory trials versus pragmatic trials." BMJ 349, no. 13 3 (2014): g6694. http://dx.doi.org/10.1136/bmj.g6694.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Sibbald, B., and C. Roberts. "Understanding controlled trials: Crossover trials." BMJ 316, no. 7146 (1998): 1719–20. http://dx.doi.org/10.1136/bmj.316.7146.1719.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

McKhann, G. M. "The Trials of Clinical Trials." Archives of Neurology 46, no. 6 (1989): 611–14. http://dx.doi.org/10.1001/archneur.1989.00520420029020.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Munayco-Guillén, Fernando, Hilbert Cevallos-Alvarado, Susy Bazán-Ruiz, Omar Espinoza-Yovera, and Rafael Pichardo-Rodríguez. "Características y tendencias de los ensayos clínicos sobre tratamientos en leucemias: análisis del Registro Peruano de Ensayos Clínicos (1995-2024)." Revista de la Facultad de Medicina Humana 25, no. 1 (2025): 126–32. https://doi.org/10.25176/rfmh.v2025i1.6825.

Full text

Abstract:

To describe the characteristics and trends of clinical trials (CTs) on leukemia registered in the Peruvian Clinical Trial Registry (REPEC, by its Spanish acronym), a descriptive study was conducted on CTs registered between 1995 and July 2024. The REPEC database was searched using the term “leukemia.” Included were CTs involving patients with acute or chronic leukemias, regardless of disease stage or prior treatment. Variables analyzed included type of leukemia, trial phase, type of product, sponsor, international registration, type of outcome, and methodological characteristics. Out of 2,058

APA, Harvard, Vancouver, ISO, and other styles

34

Feizabadi, Mansoureh, Fatima Fahimnia, Alireza Mosavi Jarrahi, Nader Naghshineh, and Shahram Tofighi. "Iranian clinical trials: An analysis of registered trials in International Clinical Trial Registry Platform (ICTRP)." Journal of Evidence-Based Medicine 10, no. 2 (2017): 91–96. http://dx.doi.org/10.1111/jebm.12248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Kuznetsova, Yulia А., and Anna V. Smirnova. "Bulletin of Clinical Studies in Q1 2021." City Healthcare 2, no. 2 (2021): 101–8. http://dx.doi.org/10.47619/2713-2617.zm.2021.v2i2;101-108.

Full text

Abstract:

Purpose. To evaluate clinical trials data since January 2021 till March 2021. Materials and methods. The information about clinical trial’s approvals from the state register of medicines of Russian Federation ministry of health website was used as the main source of the original data concerning clinical trials. The register contains all the information relating to clinical trials in Russian Federation. Results. Clinical trials data was analyzed by its type (international, local, bioequivalence), sponsorship (foreign, local), phases and disease areas. Separately COVID-19 clinical trials were co

APA, Harvard, Vancouver, ISO, and other styles

36

Bhatt, Arun. "New clinical trial rules: Academic trials and tribulations." Perspectives in Clinical Research 10, no. 3 (2019): 103. http://dx.doi.org/10.4103/picr.picr_103_19.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Nagele, Peter. "The Importance of Definitive Trials: The VIXIE Trial." Anesthesiology 136, no. 3 (2022): 403–4. http://dx.doi.org/10.1097/aln.0000000000004144.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Schoenfeld, D. "Optimizing phase II clinical trials: novel trial designs." Journal of the Peripheral Nervous System 19, S2 (2014): S18—S20. http://dx.doi.org/10.1111/jns.12081_3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Allen, Mary, Heidi Israel, Kyle Rybczyk, et al. "Trial-Related Discrimination in HIV Vaccine Clinical Trials." AIDS Research and Human Retroviruses 17, no. 8 (2001): 667–74. http://dx.doi.org/10.1089/088922201750236942.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Bousquet, Philippe Jean, Pascal Demoly, Giovanni Passalacqua, G. Walter Canonica, and Jean Bousquet. "Immunotherapy: clinical trials – optimal trial and clinical outcomes." Current Opinion in Allergy and Clinical Immunology 7, no. 6 (2007): 561–66. http://dx.doi.org/10.1097/aci.0b013e3282f1d6a4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Reed, N., and N. Siddiqui. "Trials and tribulations: obstacles to clinical trial recruitment." British Journal of Cancer 89, no. 6 (2003): 957–58. http://dx.doi.org/10.1038/sj.bjc.6601233.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Brady, M. F., J. T. Thigpen, J. B. Vermorken, and M. K. B. Parmar. "Randomised trials in ovarian cancer: trial design considerations." Annals of Oncology 10 (1999): S75—S82. http://dx.doi.org/10.1016/s0923-7534(20)31489-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Simberkoff, Michael S. "A tale of two vaccine trials: Trial 1." Current Infectious Disease Reports 4, no. 3 (2002): 235. http://dx.doi.org/10.1007/s11908-002-0084-1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Simberkoff, Michael S. "A tale of two vaccine trials: Trial 2." Current Infectious Disease Reports 4, no. 3 (2002): 236–37. http://dx.doi.org/10.1007/s11908-002-0085-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Whitehead, John, Anne Whitehead, Susan Todd, Kim Bolland, and M. Roshini Sooriyarachchi. "Mid-trial design reviews for sequential clinical trials." Statistics in Medicine 20, no. 2 (2001): 165–76. http://dx.doi.org/10.1002/1097-0258(20010130)20:2<165::aid-sim649>3.0.co;2-a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Millar, Courtney, Kathryn Baldyga, Ikechukwu Iloputaife, Alex Wolfe, Jasmin Kuo, and Lewis Lipsitz. "TRIALS AND TRIBULATIONS OF CONDUCTING A GEROSCIENCE TRIAL." Innovation in Aging 7, Supplement_1 (2023): 1144. http://dx.doi.org/10.1093/geroni/igad104.3673.

Full text

Abstract:

Abstract Emerging trials of geroscience interventions show great promise in preventing age-related diseases and disabilities. However, there are many challenges that need to be considered when conducting such trials. Our objective is to describe the major challenges when conducting a geroscience intervention, utilizing the STAMINA study as an example. The STAMINA (Senolytics To Alleviate Mobility Issues and Neurological Impairments in Aging) study is a single-arm geroscience-motivated pilot study in which 12 older adults with mild cognitive impairment and slow gait speed are asked to take 12 d

APA, Harvard, Vancouver, ISO, and other styles

47

Qureshi, Riaz. "Overview of clinical trials: trial designs and reporting." Biomedical & Life Sciences Collection 2025, no. 3 (2025): e1006740. https://doi.org/10.69645/dzyh5628.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Qureshi, Riaz. "Overview of clinical trials: history and trial elements." Biomedical & Life Sciences Collection 2025, no. 3 (2025): e1006715. https://doi.org/10.69645/iizg8884.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Frizell, John. "Trials." Nature 509, no. 7501 (2014): 526. http://dx.doi.org/10.1038/509526a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Ramamurthy, NV. "Inept media trials of clinical trials." Perspectives in Clinical Research 3, no. 2 (2012): 47. http://dx.doi.org/10.4103/2229-3485.96442.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!